Behavidence Closes $4.3M Seed Funding

Behavidence, a NYC-based provider of tools to monitor psychiatric and neurological disorders using artificial intelligence, raised $4.3M in Seed funding.

The round was led by Welltech Ventures, with participation from Arc Impact and Longevity Ventures.

The company intends to use the funds to develop its machine learning-based tools.

Founded in 2020 by Roy Cohen (CEO), Dr. Girish Srinivasan (CTO), and Dr. Janine Ellenberger (CMO), Behavidence develops machine learning based tools to detect and assist with remote monitoring and management of mental health conditions such as depression, anxiety, ADHD and more through passive digital biomarkers. The company’s products can be used as a measurement based outcome to monitor employee burnout, stress, predict relapse of conditions, screening, and remote monitoring for clinical interventions and comorbid conditions. These digital solutions have been adopted by health organizations, tech, commercial and government entities.

Behavidence has secured more than $1 million in contracts with customers across the United States, Europe, Africa and Asia. Its clients include the Department of Veterans Affairs, Discovery Health Insurance and Essen Health Care.